Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activations

BRC.6 (SWOG S1400) - A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map) - was centrally activated April 15, 2016.

The study titles of the sub-studies currently open are:

Sub-study B (BRC.6B):
A PHASE II STUDY OF GDC-0032 (TASELISIB) FOR PREVIOUSLY TREATED PI3K POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Sub-study C (BRC.6C):
A PHASE II STUDY OF PALBOCICLIB FOR PREVIOUSLY TREATED CELL CYCLE GENE ALTERATION POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Sub-study D (BRC.6D):
A PHASE II STUDY OF AZD4547 FOR PREVIOUSLY TREATED FGFR-POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)

Sub-study I (BRC.6I):
A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKER (LUNG-MAP SUB-STUDY)

The study titles of the closed sub-studies are:

Sub-study A:
A PHASE II STUDY OF MEDI4736 FOR PREVIOUSLY TREATED PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER AND NO MATCHING BIOMARKERS (LUNG-MAP SUB-STUDY)

Sub-study E:
A PHASE II/III RANDOMIZED STUDY OF RILOTUMUMAB PLUS ERLOTINIB VERSUS ERLOTINIB AS SECOND LINE THERAPY FOR C-MET POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)
_______________________________________

IND.229 - A Phase Ib Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients with HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab - was centrally activated April 21, 2016.